No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Efforts to reduce obesity may cut the prevalence of these urological conditions.
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes
It is unclear whether low testosterone is a marker or a mediator of severe and impending severe COVID-19 illness.
Each 1 unit increment in Dietary Inflammatory Index was associated with a 4.0% increase in the odds of testosterone deficiency.
Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.